A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors
Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
KeywordsGabapentin Neurontin Anti-epileptics Breast Cancer Anxiety Randomized controlled trial Cancer survivorship
The clinical trial was supported by the National Cancer Insitute. Gabpentin and placebo were provided by Pfizer. This secondary analysis was not supported by external funding.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Lavigne JE, Griggs JJ, Tu XM, Lerner DJ. Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. J Cancer Surviv. 2008 Dec;2(4):296–302Google Scholar
- 10.Montgomery SA, Tobias K, Zornberg GL et al (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771–782PubMedCrossRefGoogle Scholar
- 13.Jacox A, Carr DB, Payne R, et al. (1994) Management of cancer pain. Clinical practice guideline no. 9. AHCPR publication no. 94-0592. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, RockvilleGoogle Scholar
- 21.Speilberger CD, Gorsuch RL, Luschene R (1970) STAI manual for the state-trait anxiety inventory. Consulting Psychologists, Palo AltoGoogle Scholar
- 23.Van den Bergh R, Essink-Bot ML, Roobol MJ et al (2009) Anxiety and distress during active surveillance for early prostate cancer. Cancer 115(17):386–3878Google Scholar
- 26.Cundy K, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA (2004) XP13512: a novel gabapentin prodrug: II. Improved oral availability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311:324–333PubMedCrossRefGoogle Scholar
- 28.Gabapentin. DRUGDEX® System. Thomson Healthcare. http://www.thomsonhc.com. Accessed 7 Aug 2012